tetano
Editor, Senior Moderator
EBioMedicine. 2020 Apr 16;55:102768. doi: 10.1016/j.ebiom.2020.102768. [Epub ahead of print]
Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development.
de Alwis R[SUP]1[/SUP], Chen S[SUP]2[/SUP], Gan ES[SUP]2[/SUP], Ooi EE[SUP]3[/SUP].
Author information
Abstract
The pandemic spread of a novel coronavirus - SARS coronavirus-2 (SARS-CoV-2) as a cause of acute respiratory illness, named Covid-19, is placing the healthcare systems of many countries under unprecedented stress. Global economies are also spiraling towards a recession in fear of this new life-threatening disease. Vaccines that prevent SARS-CoV-2 infection and therapeutics that reduces the risk of severe Covid-19 are thus urgently needed. A rapid method to derive antiviral treatment for Covid-19 is the use of convalescent plasma derived hyperimmune globulin. However, both hyperimmune globulin and vaccine development face a common hurdle - the risk of antibody-mediated disease enhancement. The goal of this review is to examine the body of evidence supporting the hypothesis of immune enhancement that could be pertinent to Covid-19. We also discuss how this risk could be mitigated so that both hyperimmune globulin and vaccines could be rapidly translated to overcome the current global health crisis.
Copyright ? 2020 The Author(s). Published by Elsevier B.V. All rights reserved.
KEYWORDS:
COVID-19; Coronavirus; Polyclonal hyperimmune globulin; SARS-CoV-2; Vaccines
PMID:32344202DOI:10.1016/j.ebiom.2020.102768
Free full text
Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development.
de Alwis R[SUP]1[/SUP], Chen S[SUP]2[/SUP], Gan ES[SUP]2[/SUP], Ooi EE[SUP]3[/SUP].
Author information
Abstract
The pandemic spread of a novel coronavirus - SARS coronavirus-2 (SARS-CoV-2) as a cause of acute respiratory illness, named Covid-19, is placing the healthcare systems of many countries under unprecedented stress. Global economies are also spiraling towards a recession in fear of this new life-threatening disease. Vaccines that prevent SARS-CoV-2 infection and therapeutics that reduces the risk of severe Covid-19 are thus urgently needed. A rapid method to derive antiviral treatment for Covid-19 is the use of convalescent plasma derived hyperimmune globulin. However, both hyperimmune globulin and vaccine development face a common hurdle - the risk of antibody-mediated disease enhancement. The goal of this review is to examine the body of evidence supporting the hypothesis of immune enhancement that could be pertinent to Covid-19. We also discuss how this risk could be mitigated so that both hyperimmune globulin and vaccines could be rapidly translated to overcome the current global health crisis.
Copyright ? 2020 The Author(s). Published by Elsevier B.V. All rights reserved.
KEYWORDS:
COVID-19; Coronavirus; Polyclonal hyperimmune globulin; SARS-CoV-2; Vaccines
PMID:32344202DOI:10.1016/j.ebiom.2020.102768
Free full text